EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Two‐Year Follow‐Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA‐AF Program

Raffaele De Caterina, Martin Unverdorben, Cathy Chen, Eue-Keun Choi, Yukihiro Koretsune, Doralisa Morrone, Ladislav Pecen, Peter Bramlage, Chun-Chieh Wang, Takeshi Yamashita, Paulus Kirchhof

Clinical Cardiology · 2025

DOI: 10.1002/clc.70091 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Cardiology, 2025. Verfasst von Raffaele De Caterina und 10 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Cardiology, University of Pisa and Cardiology Division, Pisa University Hospital, Pisa, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pyridines, Thiazoles, Factor Xa Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was sponsored by Daiichi Sankyo, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Randomized clinical trials demonstrated similar efficacy and improved safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation (AF). Long‐term data in routine clinical practice are needed. Hypothesis Patients with AF receiving edoxaban at baseline continue to have low annualized effectiveness and safety event rates in the second year of follow‐up, with regional variations observed.

Methods

The Global ETNA‐AF program is a prospective, noninterventional study of patients with AF receiving edoxaban. Patient characteristics and annualized clinical event rates were assessed overall and by region across the 2‐year follow‐up. Annualized event rates of bleeding and thromboembolic events were assessed within the first year and conditionally in patients who were event‐free up to 12 months in the second year.

Results

This analysis comprised 26 805 patients from Europe ( n = 13 164), Japan ( n = 10 342), and non‐Japanese Asian regions ( n = 3299). Patients from Europe had the highest burden of comorbidities. The annualized event rates for major bleeding, any stroke, all‐cause death, and cardiovascular death varied by region. The global annualized event rates in the first and second year were 1.31%/year and 0.86%/year for major bleeding, 1.06%/year and 0.65%/year for any stroke, 0.84%/year and 0.73%/year for cardiovascular death, and 3.05%/year and 3.18%/year for all‐cause death.

Conclusion

Annualized event rates for any stroke and major bleeding remained low through 2‐year follow‐up for patients with AF receiving edoxaban at baseline. Differences in annualized event rates for all‐cause and cardiovascular mortality between Europe, Japan, and non‐Japanese Asian regions may reflect variations in baseline characteristics. Trial Registration Europe, NCT02944019; Japan, UMIN000017011; Korea/Taiwan, NCT02951039; Hong Kong, NCT03247582; and Thailand, NCT03247569.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPyridinesThiazolesFactor Xa InhibitorsStrokeThromboembolismHumansMaleFemaleAgedFollow-Up StudiesProspective StudiesHemorrhageTime FactorsTreatment OutcomeMiddle AgedEuropeRisk FactorsIncidenceJapanAdministration, Oral

Stichwörter der Autor:innen

anticoagulationatrial fibrillationdirect oral anticoagulant (DOAC)edoxabanmajor bleedingoral anticoagulantsstroke prevention

Substanzen

edoxabanPyridinesThiazolesFactor Xa Inhibitors

Autor:innen und Institutionen

  • Chair of Cardiology, University of Pisa and Cardiology Division, Pisa University Hospital, Pisa, Italy.
  • Fondazione Villa Serena per la Ricerca, Città Sant'Angelo, Italy.
  • Daiichi Sankyo, Inc., Basking Ridge, USA.
  • Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea.
  • National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Department of Surgical, Division of Cardiology, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.

Förderung

  • This study was sponsored by Daiichi Sankyo, Inc.

Zitieren

APA

De Caterina, R., Unverdorben, M., Chen, C., Choi, E. K., Koretsune, Y., Morrone, D., Pecen, L., Bramlage, P., Wang, C. C., Yamashita, T., & Kirchhof, P. (2025). Two‐Year Follow‐Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA‐AF Program. Clinical Cardiology. https://doi.org/10.1002/clc.70091

Vancouver

De Caterina R, Unverdorben M, Chen C, Choi EK, Koretsune Y, Morrone D, et al. Two‐Year Follow‐Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA‐AF Program. Clinical Cardiology. 2025. doi:10.1002/clc.70091

BibTeX
@article{DeCaterina2025,
  author = {De Caterina, Raffaele and Unverdorben, Martin and Chen, Cathy and Choi, Eue-Keun and Koretsune, Yukihiro and Morrone, Doralisa and Pecen, Ladislav and Bramlage, Peter and Wang, Chun-Chieh and Yamashita, Takeshi and Kirchhof, Paulus},
  title = {Two‐Year Follow‐Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA‐AF Program},
  journal = {Clinical Cardiology},
  year = {2025},
  doi = {10.1002/clc.70091}
}
Kostenlos starten →